Novo Nordisk

NVO factor-based stock analysis - Warren buffett Nasdaq14:24
Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients PMLiVE12:21
Newer weight-loss drugs not cost-effective at current prices TCTMD19:49
Novo Nordisk sues Mylan as part of wave of Anda suits over blockbuster semaglutide products IAM15:08
Novo Nordisk accepted back into UK pharma group after ‘sustained improvements’ get suspension… FiercePharma14:51
NVO shareholders have an opportunity to lead the Class Action against Novo Nordisk A/s – Contact Shareholder rights Law … GlobeNewswire (Press Release)22:28
Trending tickers: Tesla, Nvidia, Novo Nordisk, and Volkswagen Yahoo! UK & Ireland11:09

Latest News

In the last hour

Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 25, 2025… GlobeNewswire (Press Release)17:49

SAP Overtakes Novo Nordisk to Become Europe's Most Valuable Company Morningstar17:49

In the last 2 hours

Nvo deadline alert: Novo Nordisk (Nvo) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 25th… GlobeNewswire (Press Release)17:20

Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped The Motley Fool16:50

In the last 4 hours

Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients Quartz16:45

Outcry as Novo Nordisk Foundation looks at UPF classification FoodNavigator.com15:53

Novo Nordisk offers cheaper Wegovy for all cash-paying patients at retail pharmacy FiercePharma14:58

Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech Benzinga14:52

In the last 6 hours

Novo Nordisk Down 15% in March: Is This a Buying Opportunity? Zacks14:37

SAP unseats Novo Nordisk as Europe's largest company RTE14:30

Novo Nordisk inks deal on trial obesity drug worth up to $2bn London South East14:18

SAP overtakes Novo Nordisk as Europe’s most valuable public company amid AI-driven growth Sunday Business Post13:58

ABPI is criticised for lifting Novo Nordisk suspension despite recent breaches British Medical Journal13:55

Is Ozempic maker Novo Nordisk losing to Eli Lilly in the obesity wars? Proactive Investors (US)13:32

Software maker SAP overtakes Novo Nordisk as Europe’s largest company CyberNews13:31

SAP takes crown from Novo Nordisk as Europe's largest company Proactive Investors (UK)13:14

Novo Nordisk expands discounted Wegovy to all cash-paying US customers KELO TV13:12

Novo Nordisk Stock (NVO) Plunges as It Shells Out $2 Billion on Chinese Weight Drug TipRanks13:11

SAP overtook Novo Nordisk to become Europe's most valuable company euronews13:07

SAP leapfrogs Novo Nordisk to become Europe’s most valuable company The Irish Times13:07

German software giant SAP becomes Europe's most valuable firm Anadolu Agency13:04

Novo Nordisk looks east for another obesity therapy pharmaphorum12:56

SAP overtakes Novo Nordisk to become Europe’s largest company Financial Mail12:54

SAP takes crown from Novo Nordisk as Europe's largest companby Proactive Investors (US)12:51

In the last 8 hours

Software giant SAP becomes Europe's most valuable public company Irish Examiner12:27

Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the … PR Newswire (Press Release)12:06

Software maker SAP unseats Novo Nordisk as Europe's largest company Channel NewsAsia11:51

Novo Nordisk pays $200M upfront for United Laboratories International Holdings' triple-G obesity shot ENDPOINTS11:44

Novo Nordisk secures license to weight-loss drug candidate from China's United Labs KELO TV11:20

Earlier today

United Laboratories Partners with Novo Nordisk for UBT251 Development TipRanks10:18

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/Gip/glucagon triple… GlobeNewswire (Press Release)10:03

SAP Topples Novo to Become Europe’s Biggest Listed Company Yahoo! UK & Ireland09:52

Germany's SAP overtakes Novo Nordisk as Europe's largest company Channel NewsAsia09:29

SAP Topples Novo to Become Europe’s Most-Valuable Listed Company Yahoo! US08:51

Yesterday

Nvo final deadline: Rosen, national trial lawyers, Encourages Novo Nordisk A/S Investors to Secure Counsel Before… GlobeNewswire (Press Release)19:50 23-Mar-25

Shareholder action reminder: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk GlobeNewswire (Press Release)13:21 23-Mar-25

In the last 7 days

FDA’s Semaglutide Shortage Resolution: Legal Implications and Risks for Compounding Pharmacies JD Supra20:59 21-Mar-25

Levi & Korsinsky Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline… GlobeNewswire (Press Release)17:36 21-Mar-25

Brazil's Hypera to launch an Ozempic generic in 2026, CEO says KELO TV17:31 21-Mar-25

Eli Lilly introduces Mounjaro in India, gaining an edge over Novo Nordisk in the weight-loss drug market EasternEye17:07 21-Mar-25

Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: Nvo) Investors of Securities Class Action… GlobeNewswire (Press Release)15:34 21-Mar-25

Ozempic Copycat Makers Seek Block of FDA Drug Shortage Decision Bloomberg Law14:29 21-Mar-25

NVO Lawsuit Alert! Class Action Lawsuit Against Novo Nordisk A/S TipRanks11:13 21-Mar-25

Weight loss drug Mounjaro launched in India: Know price, how it works, side-effects, and if it’s more effective than… Indian Express09:39 21-Mar-25

Wegovy: The obesity ‘wonderdrug’ comes to Ireland, but it will cost you The Irish Times05:09 21-Mar-25

₹14,000 per month weight-loss shot is here to cash in on India’s obesity crisis The Economic Times04:16 21-Mar-25

Nvo deadline alert: Rosen, global investor counsel, Encourages Novo Nordisk A/S Investors with Losses in Excess of… GlobeNewswire (Press Release)20:46 20-Mar-25

Novo Nordisk lays out new structure for early R&D unit ENDPOINTS18:48 20-Mar-25

Eli Lilly’s popular anti-obesity drug debuts in India The Financial Express18:46 20-Mar-25

Shareholders that lost money on Novo Nordisk A/S(Nvo) should contact The Gross Law Firm about pending Class Action - Nvo GlobeNewswire (Press Release)17:02 20-Mar-25

'Not a cost-cutting exercise': Novo Nordisk CSO explains rationale behind pharma's R&D shake-up FierceBiotech14:23 20-Mar-25

Eli Lilly beats Novo Nordisk to launch diabetes and weight-loss drug Mounjaro in India The Telegraph, Calcutta11:16 20-Mar-25

Eli Lilly beats Novo Nordisk to launch weight-loss drug Mounjaro in India The Korea Times11:06 20-Mar-25

Oligonucleotides cleavage breakthrough with Vapourtec system Manufacturing Chemist09:39 20-Mar-25

Eli Lilly brings in much-awaited weight-loss drug Mounjaro to India The Hindu Business Line09:01 20-Mar-25

NVO Factor-Based Stock Analysis - Warren Buffett Nasdaq14:24 19-Mar-25

Ongoing deadline alert: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk GlobeNewswire (Press Release)13:45 19-Mar-25

Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients PMLiVE12:21 19-Mar-25

Is Novo Nordisk a No-Brainer Buy After It Dropped 40%? The Motley Fool09:03 19-Mar-25

Emisphere, Novo Nordisk Sale Suit On Track For Settlement Law36002:55 19-Mar-25

End of medicine as we know it The Financial Express01:52 19-Mar-25

Why Novo Nordisk Stock Outpaced the Market on Tuesday The Motley Fool20:50 18-Mar-25

Newer Weight-Loss Drugs Not Cost-effective at Current Prices TCTMD19:49 18-Mar-25

Novo Nordisk sues Mylan as part of wave of ANDA suits over blockbuster semaglutide products IAM15:08 18-Mar-25

Stem Cell Therapy Market Global Forecast 2025-2030: Breakthroughs in Gene Editing & Cell Therapy Propel Stem Cell… GlobeNewswire (Press Release)14:53 18-Mar-25

Wall Street Analysts Predict a 44.2% Upside in Novo Nordisk (NVO): Here's What You Should Know Zacks13:03 18-Mar-25

Novo Nordisk returns to ABPI fold after two-year suspension pharmaphorum12:37 18-Mar-25

How GLP-1 Policy Fits Into Trump’s Greenland Strategy, And Five Other Health Tech Developments Forbes12:02 18-Mar-25

Big Pharma on edge as US-EU tariff spat poses risk for drug sales Daily Sabah11:04 18-Mar-25

Big pharma fears drugs in crosshairs of US-EU tarrif spat RTE11:01 18-Mar-25

Arbor raises $74M amid genetic medicine’s funding slump BioPharma Dive10:49 18-Mar-25

Big tech meets biotech: Recursion and the AI gold rush in pharma Pharmaceutical Technology10:41 18-Mar-25

Novo Nordisk industry membership reinstated European Pharmaceutical Review09:13 18-Mar-25

Weight loss drug supply races Chemistry World Magazine08:53 18-Mar-25

Big pharma fears best-selling drugs in crosshairs of US-EU tariff spat Yahoo! US06:13 18-Mar-25

Rosen, A top-ranked firm, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in… GlobeNewswire (Press Release)23:45 17-Mar-25

UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension Benzinga19:09 17-Mar-25

Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 25, 2025 to… GlobeNewswire (Press Release)18:30 17-Mar-25

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo… PR Newswire (Press Release)16:31 17-Mar-25

Novo Nordisk membership in UK pharma body restored after suspension KELO TV16:19 17-Mar-25

Novo Nordisk accepted back into UK pharma group after ‘sustained improvements’ get suspension… FiercePharma14:51 17-Mar-25

Novo Nordisk presents new semaglutide cardiovascular data across multiple chronic diseases at… PR Newswire (Press Release)12:02 17-Mar-25

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation The Motley Fool10:53 17-Mar-25

Anti-Obesity Drugs Market Industry Trends, Sales Forecast, Key Players and Global Forecasts to 2035: Semaglutide &… GlobeNewswire (Press Release)09:41 17-Mar-25

The weight loss drug shortage is over — and some patients are 'panicking' Quartz09:07 17-Mar-25

Novo Nordisk and Bangkok Unite for a Healthier Future Bangkok Post08:47 17-Mar-25

Lilly Korea pushes to launch obesity drug Mounjaro as vial injection in Korea Korea Biomedical Review02:27 17-Mar-25

In the last month

Upcoming Dividend Run For NVO? Nasdaq14:43 16-Mar-25

Investor deadline approaching: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk GlobeNewswire (Press Release)13:13 15-Mar-25

Drugmakers agree to participate in second round of price negotiations Yahoo! UK & Ireland22:22 14-Mar-25

Rosen, leading investor counsel, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in… GlobeNewswire (Press Release)21:57 14-Mar-25

Monksland company's choir wins singing award for second year running The Westmeath Independent19:00 14-Mar-25

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J Zacks15:03 14-Mar-25

Novo Nordisk: Stock Plunges, But It May Be Time To Load Up Seeking Alpha14:11 14-Mar-25

Zacks Market Edge Highlights: Tesla, NVIDIA, JPMorgan Chase, Exxon Mobil and Novo Nordisk Zacks14:02 14-Mar-25

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year Simply Wall St11:32 14-Mar-25

Illexcor Stake Gets Zydus Once-Daily Candidate For Sickle Cell Disease Scrip Pharma Intelligence09:09 14-Mar-25

Illexcor Stake Gets Zydus Sickle Cell Disease Contender Like Pfizer’s Oxbryta Scrip Pharma Intelligence08:38 14-Mar-25

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk Seeking Alpha20:05 13-Mar-25

Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses. March 25, 2025 Deadline to file … GlobeNewswire (Press Release)19:34 13-Mar-25

Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today Quartz16:57 13-Mar-25

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy TipRanks16:48 13-Mar-25

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update Zacks16:36 13-Mar-25

UiPath plunges on weak outlook, Novo Nordisk upgrade: Top Stocks Yahoo! UK & Ireland14:47 13-Mar-25

Subcutaneous Cagrilintide, Semaglutide Shows Significant Weight Loss in Type 2 Diabetes Trial Pharmacy Times14:20 13-Mar-25

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak Yahoo! US14:06 13-Mar-25

Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs. SELF Magazine12:13 13-Mar-25

Donald Trump's $1.4 trillion tariff threats scramble business plans, US companies form… Mint09:15 13-Mar-25

Pioneering plant microbiome research: Julia Vorholt receives 2025 Novonesis Biotechnology Prize … PR Newswire (Press Release)08:04 13-Mar-25

Novo Nordisk joins forces with Seoul to boost health equity through 'Cities for Better Health' initiative Korea Biomedical Review06:56 13-Mar-25

Roche, Zealand sign deal: What it means for weight loss drug space Yahoo! US20:16 12-Mar-25

Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4% Yahoo! US19:14 12-Mar-25

Novo Nordisk, Starbucks shares slumping: Trending Tickers Yahoo! US17:02 12-Mar-25

iRobot, Target, Novo Nordisk vs. Roche: Market Minute Yahoo! UK & Ireland16:22 12-Mar-25

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped The Motley Fool16:14 12-Mar-25

view more headlines

24 Mar 17:49

About our Novo Nordisk news

Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our NewsNow feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.

Novo Nordisk

Latest News

About our Novo Nordisk news

Pharmaceuticals Top Stories

UK Top Stories

World Top Stories